HDAC inhibitors-new generation of target specific treatment

Mini-Reviews in Medicinal Chemistry

Volumn 10, Issue 2, 2010, Pages 1263-1276

  Chavan, A V ^a   Somani, R R ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

Author keywords

Chemistry; Hdac inhibitor; Histone deacetylase; Therapeutic applications

Indexed keywords

APICIDIN; BENZAMIDE; CYCLIN A; CYCLIN D; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; ENTINOSTAT; EPOXIDE; GENOMIC DNA; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; KETONE DERIVATIVE; MOCETINOSTAT; POLYGLUTAMINE; PROTEIN BAX; PROTEIN BCL 2; ROMIDEPSIN; SHORT CHAIN FATTY ACID; SIRTUIN 2; STAT6 PROTEIN; TACEDINALINE; TETRAPEPTIDE; TUBACIN; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; HISTONE;

ACYLATION; ANTIANGIOGENIC ACTIVITY; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DEACYLATION; DEHYDRATION; DIARRHEA; DRUG WITHDRAWAL; ERYTHRODERMA; FATIGUE; HEMATOLOGIC MALIGNANCY; HUMAN; HUNTINGTON CHOREA; HYPOXIA; INFLAMMATORY DISEASE; MENTAL DISEASE; MOLECULARLY TARGETED THERAPY; NAUSEA; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROMYELOCYTIC LEUKEMIA; RUBINSTEIN SYNDROME; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TASTE DISORDER; THROMBOCYTOPENIA; ANIMAL; CENTRAL NERVOUS SYSTEM DISEASE; CHEMISTRY; METABOLISM; REVIEW;

ACYLATION; ANIMALS; CENTRAL NERVOUS SYSTEM DISEASES; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84871163185     PISSN: 13895575     EISSN: 18755607     Source Type: Journal    
DOI: 10.2174/13895575110091263     Document Type: Article

References (113)

1. Epping, M.T.; Bernards, R. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Int. J. Biochem. Cell. Biol., 2009; 41, 16-20.
2. Zheng, Y.G.; Wu, J.; Chen, Z.; Goodman, M. Chemical regulation of epigenetic modifications: opportunities for new cancer therapy. Med. Res. Rev., 2008, 28(5), 645-687.
3. Glaser, K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem. Pharmacol., 2007, 74, 659-671.
4. Villar-garea, A.; Esteller, M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int. J. Cancer., 2004, 112, 171-178.
5. Yoo, C.B.; Jones, P.A. Epigenetic therapy of cancer: past, present and future. Nat. Rev. Drug. Discov., 2006, 5(1), 37-50.
6. Kristeleit, R.; Stimson, L.; Workman, P.; Aherne, W. Histone modification enzymes: novel targets for cancer drugs. Expert. Opin. Emerg. Drugs., 2004, 9(1), 135-154.
7. Monneret, C. Histone deacetylase inhibitors. Eur. J Med. Chem., 2005; 40, 1-13.
8. Luger, K.; Mader, A.W.; Richmond, R.K.; Sargent, D.F.; Richmond, T.J. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature, 1997, 389, 251-260.
9. P. A. Transcriptional control at regulatory checkpoints by histone deacetylases: Molecular connection between cancer and chromatin. Hum. Mol. Genet., 2001, 10, 693-698.
10. Norton, V.G.; Imai, B.S.; Yau, P.; Bradbury, E.M. Histone acetylation reduces nucleosome core particle linking number change. Cell, 1989, 57, 449-457.
11. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug. Discov., 2006, 5, 769-784.
12. De Ruijter, A.J.M.; Van Gennip, A.H.; Caron, H.N.; KEMP, S.; Van Kuilenburg, A.B.P. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem. J., 2003, 370, 737-749.
13. Bjerling, P.; Silverstein, R.A.; Thon, G.; Caudy, A.; Grewal, S.; Ekwall, K. Functional Divergence between Histone Deacetylases in Fission Yeast by Distinct Cellular Localization and In vivo Specificity. Mol. Cell. Biol., 2000, 22(7), 2170-2181.
14. Blander, G.; Guarente, L. The Sir2 family of protein deacetylases. Annu. Rev. Biochem., 2004, 73, 417-435.
15. Witt, O.; Deubzer, H.E.; Milde, T.; Oehme, I. HDAC family: What are the cancer relevant targets? Can. Lett., 2009, 277(1), 8-21.
16. Blackwell, L.; Norris, J.; Suto, C.M.; Janzen, W.P. The Use of Diversity Profiling to Characterize Chemical Modulators of the Histone Deacetylases. Life Sci., 2008, 82, 1050-1058.
17. Johnstone, R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug. Discov., 2002, 1, 287-299.
18. Wen, Y.D.; Perissi, V.; Staszewski, L.M.; Yang, W.M.; Krones, A.; Glass, C.K.; Rosenfeld, M.G.; Seto, E. The histone deacetylase-3 complex contains nuclear receptor corepressors. Proc. Natl. Acad. Sci. USA, 2000, 97, 7202-7207.
19. Marks, P.; Rifkind, R.A.; Richon, V.M.; Breslow, R.; Miller, T.; Kelly, W.K. Histone deacetylases and cancer: causes and therapies. Nat. Rev. Cancer, 2001, 1, 194-202.
20. Hubbert, C.; Guardiola, A.; Shao, R.; Kawaguchi, Y.; Ito, A.; Nixon, A.; Yoshida, M.; Wang, X.F.; Yao, T.P. HDAC6 is a microtubule-associated deacetylase. Nature, 2002, 417, 455-458.
21. Kovacs, J.J.; Murphy, P.J.; Gaillard, S.; Zhao, X.; Wu, J.T.; Nicchitta, C.V.; Yoshida, M.; Toft, D.O.; Pratt, W.B.; Yao, T.P. HDAC 6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell., 2005, 18, 601-607.
22. R. Structure of Histone Deacetylases: Insights into Substrate Recognition and Catalysis. Structure, 2001, 9, 1127-1133.
23. Marmorstein, R. Structure and chemistry of the Sir2 family of NAD -dependent histone/protein deactylases. Biochm. Soc. Trans., 2004, 32, Part 6, 904-909.
24. Finnin, M.S.; Donigian, J.R.; Cohen, A.; Richon, V.M.; Rifkind, R.A.; Marks, P.A.; Breslow, R.; Pavletich, N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors, Nature, 1999, 401, 188-193.
25. Buggy, J.J.; Sideris, M.L.; Mak, P.; Lorimer, D. D.; McIntosh, B.; Clark, J.M. Cloning and characterization of a novel human histone deacetylase, HDAC8. Biochem. J., 2000, 350, 199-205.
26. Newmark H.L.; Lupton J.R.; Young C.W. Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancar Lett., 1994, 78, 1-5.
27. Tsuji, N.; Kobayashi, M.; Nagashima, K.; Wakisaka, Y.; Koizumi, K. A new antifungal antibiotic, trichostatin. J. Antibiot. (Tokyo), 1976, 29, 1-6.
28. Yoshida, M.; Kijima M.; Akita, M.; Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem., 1990, 265, 17174-17179.
29. Richon, V.M.; Emiliani, S.; Verdin, E.; Webb, Y.; Breslow, R.; Rifkind R.A.; A. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl. Acad. Sci. USA, 1998, 95, 3003-3007.
30. Kim, Y.B.; Lee, K.H.; Sugita, K.; Yoshida, M.; Horinouchi, S. Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene, 1999, 18, 2461-2470.
31. Kijima, M.; Yoshida, M.; Sugita, K.; Horinouchi, S.; Beppu, T. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase. J. Biol. Chem., 1993, 268, 22429-22435.
32. Nakajima, H.; Kim, Y.B.; Terano, H.; Yoshida, M.; Horinouchi, S. FR901228, A potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp. Cell. Res., 1998, 241, 126-133.
33. Xie, A.; Liao, C.; Li, Z.; Ning, Z.; Hu, W. Quantitative structureactivity relationship study of histone deacetylase inhibitor.
34. Lu, X.; Shi, L.; Zhou, J. Curr. Med. Chem. -Anti-Cancer Agents, 2004, 4, 273-299.
35. Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. U S A, 1999, 96, 4592-4597.
36. Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat. Rev. Drug. Discov., 2007, 6, 21-22.
37. Bieliauskas, A.V.; Weerasinghe, S.V.W.; Pflum, M. K. H. Structural requirements of HDAC inhibitors: SAHA analogs functionalized adjacent to the hydroxamic acid. Bioorg. Med. Chem. Lett., 2007, 17, 2216-2219.
38. Andrianov, V.; Gailite, V.; Lola, D.; Loza, E.; Semenikhina, V.; Kalvinsh, I.; Finn, P.; Dumong V.; Petersen, James; W.A. Ritchie, Khan, N.; Tumber, A.; Collins, L. S.; Vadlamudi, S.M.; Bjorkling, F.; Sehested, M. Novel amide derivatives as inhibitors of histone deacetylase: Design, synthesis and SAR. Eur. J. Med. Chem., 2009, 44, 1067-1085.
39. Chen, P.C.; Patil, V.; Guerrant, W.; Green, P.; Oyelere, A.K. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. Bioorg. Med. Chem., 2008, 16, 4839-4853.
40. Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B.A. A stepwise huisgen cycloaddition process: Copper(I)-Catalyzed regioselective ligation of azides and terminal alkynes. Angew Chem. Int. Ed., 2002, 41, 2596-2599.
41. Tornoe, C.W.; Christensen, C.; Meldal, M. Peptidotriazoles on solid phase: [1,2,3-triazoles by regiospecific copper(I)-catalyzed 1,3-dipolar cycloadditions of terminal alkynes to azides. J. Org. Chem., 2002, 67, 3057-3064.
42. Bock, V.D.; Hiemstra, H.; van Maarseveen, J.H. Cu-catalyzed alkyne-azide "click" cycloadditions from a mechanistic and synthetic perspective. Eur. J. Med. Chem., 2006, 51-68.
43. HDAC Fluorimetric Assay/Drug Discovery Kit-AK-500 Manual. Fluorescent Assay System (BIOMOL International, Plymouth Meeting, PA), 2005.
44. Lavoie, R.; Bouchain, G.; Frechette, S.; Woo, S. H.; Khalil, E. A.; Fournel, M.; Yan, P. T.; Claude M.; Li, Z., Bestermanb, J.; Delorme, D. Bioorg. Med. Chem. Lett., 2001, 11, 2847-2850.
45. Jung, M.; Hoffmann, K.; Brosch, G.; Loidl, P. Analogues of Trichostatin A and Trapoxin B as histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 1997, 7, 1655-1658.
46. Jung, M.; Brosch, G.; Scherf, H.; Loidl, P. Amide analogs of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem., 1999, 42, 4669-4679.
47. Woo, S.H.; Frechette, S.; Bouchain, G.; Vaisburg, A.; Bernstein, N.; Moradei, O.; Leit, S.; Allan, M.; Fournel, M.; Trachy-Bourget, M.C.; Li, Z.; Besterman, J.M.; Delorme, D. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. J. Med. Chem., 2002, 45, 2877-2885.
48. Curtin, M.L.; Garland, R.B.; Heyman, H.R.; Frey, R.R.; Michaelides, M.R.; Li, J.; Pease, L.J.; Glaser, K.B.; Marcotte, P.A.; Davidsen, S.K,; Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC). Bioorg. Med. Chem. Lett., 2002, 12, 2919-2923.
49. Dai, Y.; Guo, Y.; Guo, J.; Pease, L.J.; Li, J.; Marcotte, P.A.; Glaser, K.B.; Tapang, P.; Albert, D.H.; Richardson, P.L.; Davidsen, S.K.; Michaelides, M.R. Indole amide hydroxamic acids as potent inhibitors of histone deacetylases. Bioorg. Med. Chem. Lett., 2003, 13, 1897-1901.
50. Lavoie, R.; Bouchain, G.; Frechette, S.; Woo, S.H.; Khalil, E. A.; Leit S. Design and Synthesis of a Novel Class of Histone Deacetylase Inhibitors. Bioorg. Med. Chem. Lett., 2001, 11, 2847-2850.
51. Arts, J.; Emelen, K.V.; Angibaud, P.; Brandt, S. V.; Poncelet, V.; Verdonck, M. Molecular Targets and Cancer Therapeutics, AACRNCI-EORTC International Conference, Boston, MA, USA, 2003, November 17-21, (Abstract #A153).
52. Grant, S. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?, Leukemia, 2004, 18(12), 1931-1933.
53. Fuino, L.; Bali, P.; Wittmann, S.; Donapaty, S.; Guo, F.; Yamaguchi, H. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol. Cancer Ther., 2003, 2(10), 971-984.
54. Plumb, J.A.; Finn, P.W.; Williams, R.J.; Bandara, M.J.; Romero, M.R.; Watkins, C.J. Pharmacodynamic responses and inhibition of growth of human tumour xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther, 2003, 2(8), 721-728.
55. Watkins, C.J.; Romero, M.R.; Maria, R.; Ritchie, J.; Finn, P.W.; Kalvinsh, I. PCT Int. Appl. WO 03 82, 288; Chem. Abstract 139, 2003, 307794q.
56. Furumai, R.; Matsuyama, A.; Kobashi, N.; Lee, K.H.; Nishiyama, M.; Nakajima, H. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res, 2002, 62, 4916-4921.
57. Piekarz, R.; Frye, R.; Turner, M.; Wright, J.; Allen, S.; Kirschbaum, M. Phase II trial of romidepsin, FK228, in cutaneous and peripheral T-cell lymphoma: clinical activity and molecular markers. Blood, 2006, 108(11), 2469.
58. Itazaki, H.; Nagashima, K.; Sugita, K.; Yoshida, H.; Kawamura, Y.; Yasuda, Y.; Matsumoto, K.; Ishii, K.; Uotani, N.; Nakai, H.; Terui, A.; Yoshimatsu, S.; Ikenishi, Y.; Nakawaga, Y. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents. J. Antibiot., 1990, 43, 1524-1532.
59. Jones, P.; Altamura, S.; Chakravarty, P. K.; Cecchetti, O.; De Francesco, R.; Gallinari, P.; Ingenito, R.; Meinke, P.T.; Petrocchi, A. A series of novel, potent, and selective histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 5948-5952.
60. Kwon, S.H.; Ahn, S.H.; Kim, Y.K.; Bae, G.U.; Yoon, J.W.; Hong, S. Apicidin, a histone deacetylase inhibitor, induces apoptosis and Fas/Fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem., 2002, 277, 2073-2080.
61. Hess-Stumpp, H.; Bracker, T.U.; Henderson, D.; Politz, O. MS-275, a potent orally available inhibitor of histone deacetylase-the development of anticancer agents. Int. J. Biochem. Cell. Biol., 2007, (7-8), 1388-1405.
62. Seelig, M.H.; Berger, M.R. Efficacy of dinaline and its methyl and acetyl derivatives against colorectal cancer in vivo and in vitro. Eur. J. Cancer, 1996, 32A (11), 1968-1976.
63. Hamblett, C.L.; Methot, J.L.; Mampreian, D.M.; Sloman, D.L.; Stanton, M.G.; Kral, A.M.; Fleming, J.C.; Cruz, J.C.; Chenard, M.; Ozerova, N.; Hitz, A. M.; Wang, H.; Deshmukh, S.V.; Nazef, N.; Harsch, A.; Hughes, B.; Miller, T. A. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors. Bioorg. Med. Chem. Lett., 2007, 17, 5300-5309.
64. Jiao, J.; Fang, H.; Wang, X.; Guan, P.; Yuan, Y.; Xu, W. Design, synthesis and preliminary biological evaluation of N-hydroxy-4-(3-phenylpropanamido)benzamide (HPPB) derivatives as novel histone deacetylase inhibitors. Eur. J. Med. Chem., 2009, 44, 4470-4476
65. Suzuki, T.; Nagano, Y.; Matsuura, A.; Kohara, A.; Ninomiya, S.-I.; Kohda, K.; Miyata, N. Novel histone deacetylase inhibitors: design, synthesis, enzyme inhibition and binding made study of SAHAbased non-hydroxamates. Bioorg. Med. Chem. Lett., 2003, 13, 4321-4326.
66. Frey, R.R.; Wada, C.K.; Garland, R.B.; Curtin, M.L.; Michaelides, M.R; Li, J.; Pease, L.J.; Glaser, K.B.; Marcotte, P.A.; Bouska, J.J.; Murphy, S.S.; Davidsen, S.K. Trifluoromethyl ketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett., 2002, 12, 3443-3447.
67. Vasudevan, A.; Ji, Z.; Frey, R.R.; Wada, C.K.; Steinman, D.; Heyman, H.R.; Guo, Y.; Curtin, M.L.; Guo, J.; Li, J.; Pease, L.; Glaser, K.B.; Marcotte, P.A.; Bouska, J.J.; Davidsen, S.K.; Michaelides, M.R. Heterocyclic ketones as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett., 2003, 13, 3909-3913.
68. Wada, C.K.; Frey, R.R.; Ji, Z.; Curtin, M.L.; Garland, R.B.; Holms, J.H.; Li, J.; Pease, L.J.; Guo, J.; Glaser, K.B.; Marcotte, P.A.; Richardson, P.L.; Murphy, S.S.; Bouska, J.J.; Tapang, P.; Magoc, T.J.; Albert, D.H.; Davidsen, S.K.; Michaelides, M.R.; Alpha-keto amides as inhibitors of histone deacetylase. Bioorg. Med. Chem. Lett., 2003, 13, 3331-3335.
69. Zheng, Y.G.; Wu, J.; Chen, Z.; Goodman, M. Chemical regulation of epigenetic modification: oppurtunities for new cancer therapy. Med. Res. Rev., 2008, 28(5), 645-687.
70. North, B.J.; Verdin, E. Sirtuins: Sir2-related NAD-dependent protein deacetylases Genome Biol., 2004, 5(5), Article 224.
71. Khan, N.; Jeffers, M.; Kumar, S.; Hackett, C.; Boldog, F.; Khramtsov, N.; Qian, X.; Mills, E.; Berghs, S.C.; Carey, N.; Finn, P.W.; Collins, L.S.; Tumber, A.; Ritchie, J.W.; Jensen' P. B.; Lichenstein, H.S.; Sehested, M. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J., 2008, 409, 581.
72. Bieliauskas, A.V.; Pflum, M. K. H. Isoform-selective histone deacetylase inhibitors. Chem. Soc. Rev., 2008, 37(7), 1402-1413.
73. Furumai, R.; Komatsu, Y.; Nishino, N.; Khochbin, S.; Yoshida, M.; Horinouchi, S. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proc. Natl. Acad. Sci. USA, 2001, 98, 87-92.
74. Mai, A.; Massa, S.; Pezzi, R.; Simeoni, S.; Rotili, D.; Nebbioso, A.; Scognamiglio, A.; Altucci, L.; Loidl, P.; Brosch, G. Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides. J. Med. Chem., 2005, 48, 3344-3353.
75. Beckers, T.; Burkhardt, C.; Wieland, H.; Gimmnich, P.; Ciossek, T.; Maier, T.; Sanders, K. Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int. J. Cancer, 2007, 121, 1138-1148.
76. Hu, E.; Dul, E.; Sung, C-M.; Chen, Z.; Kirkpatrick, R.; Zhang, GF.; Johanson, K.; Liu, R.; Lago, A.; Hofmann, G.; Macarron, R.; De Los Frailes, M.; Perez P.; Krawiec, J.; Winkler J.; Jaye, M. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther., 2003, 307, 720-728.
77. Park, J.H.; Jung, Y.; Kim, T.Y.; Kim, S.G.; Jong, H.S.; Lee, J.W.; Kim, D.K.; Lee, J.S.; Kim, N.K.; Kim, T.Y.; Bang, Y.J. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer. Res., 2004, 10, 5271-5281.
78. Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J.J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia, 2008, 22, 1026-1034.
79. Gurvich, N.; Tsygankova, O.M.; Meinkoth, J.L.; Klein, P.S. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res., 2004, 64, 1079-1086.
80. Guardiola, A.R.; Yao, T.P. Molecular cloning and characterization of a novel histone deacetylase HDAC10. J. Biol. Chem., 2002, 277, 3350-3356.
81. Zhang, C.; Richon, V.; Ni, X.; Talpur, R.; Duvic, M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic effect. J. Invest. Dermatol., 2005, 125, 1045-1052.
82. Duvic, M.; Zhang, C. Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma. Br. J. Cancer, 2006, 95, S13-S19.
83. Johnstone, R.W.; Licht, J.D. Histone deacetylase inhibitors in cancer therapy: Is transcription the primary target? Cancer Cell, 2003, 4, 413-418.
84. Rosato, R.R.; Almenara, J.A.; Grant, S.; The histone deacetylase inhibitor ms-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21cip1/waf1 1. Cancer Res., 2003, 63, 3637-3645.
85. Subramanian, C.; Opipari, Jr A.W.; Bian, X.; Castle, V.P.; Kwok, R.P.; Subramanian C, Opipari Jr AW, Bian X, Castle VP, Kwok RP. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA, 2005, 102, 4842-4847.
86. Cohen, H.Y.; Lavu, S.; Bitterman, K.J.; Hekking, B.; Imahiyerobo, C.; Miller, C. Acetylation of the c terminus of ku70 by cbp and pcaf controls bax-mediated apoptosis. Mol. Cell, 2004, 13, 627-638.
87. Ungerstedt, J.S.; Sowa, Y.; Xu, W.S.; Shao, Y.; Dokmanovic, M.; Perez, G. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc. Natl. Acad. Sci. USA, 2005, 102, 673-678.
88. Kwon, S.H.; Ahn, S.H.; Kim, Y.K.; Bae, G.U.; Yoon, J.W.; Hong, S. Apicidin, a histone deacetylase inhibitor, induces apoptosis and fas/fas ligand expression in human acute promyelocytic leukemia cells. J. Biol. Chem., 2002, 277, 2073-2080.
89. Glick, R.D.; Swendeman, S.L.; Coffey, D.C.; Rifkind, R.A.; Marks, P.A.; Richon, V.M. Hybrid polar histone deacetylase inhibitor induces apoptosis and cd95/cd95 ligand expression in human neuroblastoma. Cancer Res., 1999; 59, 4392-4399.
90. Nebbioso, A.; Clarke, N.; Voltz, E.; Germain, E.; Ambrosino, C.; Bontempo, P. al. Tumor-selective action of hdac inhibitors involves trail induction in acute myeloid leukemia cells. Nat. Med., 2005; 11, 77-84.
91. Insinga, A.; Monestiroli, S.; Ronzoni, S.; Gelmetti, V.; Marchesi, F.; Viale, A.; Inhibitors of histone deacetylases induce tumorselective apoptosis through activation of the death receptor pathway. Nat. Med., 2005; 11, 71-76.
92. Liu, T.; Kuljaca, S.; Tee, A.; Marshall, G.M. Histone deacetylase inhibitors: multifunctional anticancer agents. Cancer Treat. Rev., 2006, 32, 157-165
93. Michaelis, M.; Michaelis, U.R.; Fleming, I.; Suhan, T.; Cinatl, J.; Blaheta, R.A. Valproic acid inhibits angiogenesis in vitro and in vivo. Mol. Pharmacol., 2004, 65, 520-527.
94. Zgouras, D.; Becker, U.; Loitsch, S.; Stein, J. Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem. Biophys. Res. Commun., 2004, 316, 693-697.
95. Kim, M.S.; Kwon, H.J.; Lee Baek, J.H.; Jang, J.E.; Lee, S.W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med., 2001; 7, 437-443.
96. Mahon, P.C.; Hirota, K.; Semenza, G.L. FIH-1: a novel protein that interacts with HIF-1 and VHL to mediate repression of HIF-1 transcriptional activity. Genes. Dev., 2001, 15, 2675-2686.
97. Kim, E.J.; Hess, S.; Richardson, S.K.; Newton, S.; Showe, L.C.; Benoit, B.M. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J. Clin. Invest., 2005, 115, 798-812.
98. Blanchard, F.; Chipoy, C. Histone deacetylase inhibitors: new drug for the treatment of inflammatory diseases? Reviews-Drug Discov. Today, 2005, 10(3), 197-204.
99. Ito, K.; Caramori, G.; Lim, S. Expression and activity of histone deacetylases (HDACs) in human asthmatic airways. Am. J. Respir. Crit. Care Med., 2002, 166, 392-396.
100. To, Y.; Elliott, W.M.; Ito, M.; Total histone deacetylase activity decreases with increasing clinical stage of COPD. Am. J. Respir. Crit. Care Med., 2004, 169, A276
101. Barnes, P.J.; Adcock, I.M.; Ito, K. Histone acetylation and deacetylation: importance in inflammatory lung diseases. Eur. Respir. J., 2005, 25, 552-563.
102. Watt, A.P.; Schock, B.C.; Ennis, M. Neutrophils and eosinophils: clinical implications of their appearance, presence and disappearance in asthma and COPD. Curr. Drug Targets-Inflammation Allergy, 2005, 4,415-423.
103. Boyle, G.M.; Martyn, A.C.; Parsons, P.G.; Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res., 2005, 18,160-166.
104. Dokmanovic, M.; Marks, P.A.; Prospects: histone deacetylase inhibitors. J. Cell. Biochem., 2005, 96, 293-304.
105. Choi, J.H.; Oh, S.W.; Kang, M.S.; Kwon, H.J.; Oh, G.T.; Kim, D.Y. Trichostatin A attenuates airway inflammation in mouse asthma model. Clin. Exp. Allergy, 2005, 35, 89-96.
106. Kankaanranta, H.; Janka-Junttila, M.; Ilmarinen-Salo, P.; Ito, K.; Jalonen, U.; Ito, M.; Adcock, I. M.; Moilanen, E.; Zhang, X. Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils, J. Inflamm., 2010, 7,9-22.
107. Mishra, N.; Reilly, C.M.; Brown, D.R.; Ruiz, P.; Gilkeson, G.S. Histone deacetylase inhibitors modulate renal disease in the MRLlpr/ lpr mouse. J. Clin. Invest., 2003, 111, 539-552.
108. Mishra, N. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc. Natl. Acad. Sci. USA., 2001; 98, 2628-2633.
109. Kazantsev, A.G.; Thompson, L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov., 2008; 7, 854-868.
110. Cummings, C. J.; Zoghbi, H. Y. Trinucleotide repeats: mechanisms and pathophysiology. Annu. Rev. Genomics Hum. Genet., 2000, 1, 281-328.
111. Ross, C.A.; Poirier, M.A. Protein aggregation and neurodegenerative disease. Nat. Med., 2004, 10 Suppl., 10-17. Nat. Med., 2004, 10 Suppl., 10-17.
112. Kimura, Y.; Lee, W-C M.; Troy J. Littleton. Therapeutic prospects for the prevention of neurodegeneration in Huntington's disease and the polyglutamine repeat disorders. Mini-Rev. Med. Chem., 2007, 7, 99-106.
113. Steffan, J. S.; Bodai, L.; Pallos, J.; Poelman, M.; McCampell, A.; Apostol, B.L.; Kazantsev, A.; Schmidt, E.; Zhu, Y. Z.; Greenwald, M.; Kurokawa, R.; Housman, D.E.; Jackson, G. R.; Marsh, J.; Thompson, L. M. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature, 2001, 413, 739-743.